Yong Ju Liang

TL;DR: Investigation of the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABCsubfamily G member 2 (ABCG2) transporters found it reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function.

TL;DR: It is shown that apatinib reverses ABCB1- and ABCG2-mediated MDR by inhibiting their transport function, but not by blocking the AKT or ERK1/2 pathway or downregulating ABCB 1 or ABCG 2 expression.

TL;DR: The results suggest that administration of RNAi targeted MDR1 gene can effectively reverse MDR both in vitro and in vivo models.

TL;DR: The results suggest that apatinib could target to SP cells and ABCB1-overexpressing leukemia cells to enhance the efficacy of chemotherapeutic drugs.

TL;DR: The results showed that sunitinib completely reverse drug resistance mediated by ABCG2 at a non-toxic concentration of 2.5muM and has no significant reversal effect on ABCB1-, ABCC1- and LRP-mediated drug resistance, although a small synergetic effect was observed in combining sunit inib and conventional chemotherapeutic agents.